SBRA

$19.740.66%0.13

Vorbörslich: 19.75+0.01 +0.05%

Sabra Healthcare Reit Inc (SBRA)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$19.61

Offen:

$19.76

24-Stunden-Volumen:

2,015,627

Relatives Volumen:

0.90

Marktkapitalisierung:

$5.04B

Einnahmen:

$810.81M

Nettoeinkommen (Verlust:

$156.02M

KGV:

31.24

EPS:

$0.6319

Netto-Cashflow:

$373.47M

1W Leistung:

-0.20%

1M Leistung:

+3.03%

6M Leistung:

-3.05%

1Y Leistung:

+10.77%

1-Tages-Spanne:

$0.00$0.00

1-Wochen-Bereich:

$18.89$19.96

52-Wochen-Spanne:

$17.25$22.77

Sabra Healthcare Reit Inc Aktie (SBRA) Unternehmensprofil

Firmenname

Sabra Healthcare Reit Inc

Sektor

Real Estate

Branche

REIT - Healthcare Facilities

Telefon

888-393-8248

Adresse

1781 FLIGHT WAY, TUSTIN, CA, USA

Mitarbeiter

Nächster Verdiensttermin

2026-11-02

Neueste SEC-Einreichungen

SEC

SBRA-Diskussionen auf X

SBRA vs. WELL, VTR, OHI, DOC, AHR vergleichen

Aktien	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SBRA Sabra Healthcare Reit Inc	$5.04B	$810.81M	$156.02M	$373.47M	$0.6319
WELL Welltower Inc	$172.10B	$11.75B	$1.46B	$2.19B	-$0.6014
VTR Ventas Inc	$44.84B	$6.13B	$272.21M	$1.38B	$0.5521
OHI Omega Healthcare Investors Inc	$14.24B	$1.24B	$655.98M	$857.80M	$2.06
DOC Healthpeak Properties Inc	$13.12B	$2.87B	$250.10M	$1.13B	$0.3188
AHR American Healthcare Reit Inc	$11.67B	$2.37B	$101.67M	$169.19M	$0.5775

Sabra Healthcare Reit Inc Aktie (SBRA) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-09-10	Eingeleitet	Huntington	Outperform
2026-08-06	Hochstufung	Raymond James	Underperform → Mkt Perform
2026-07-08	Herabstufung	Truist	Buy → Hold
2026-07-07	Eingeleitet	Barclays	Overweight
2026-06-23	Herabstufung	Citigroup	Buy → Neutral
2026-06-17	Resumed	Raymond James	Underperform
2025-11-18	Eingeleitet	UBS	Neutral
2025-10-01	Eingeleitet	Cantor Fitzgerald	Neutral
2025-01-17	Herabstufung	Truist	Buy → Hold
2025-01-07	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2024-12-05	Herabstufung	Mizuho	Outperform → Neutral
2024-10-01	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-09-13	Hochstufung	Citigroup	Neutral → Buy
2024-01-30	Eingeleitet	Deutsche Bank	Buy
2023-10-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-10-16	Hochstufung	Wells Fargo	Underweight → Equal Weight
2023-10-10	Hochstufung	BofA Securities	Neutral → Buy
2023-10-03	Eingeleitet	Wedbush	Outperform
2023-09-20	Hochstufung	Jefferies	Hold → Buy
2023-08-11	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-27	Eingeleitet	Berenberg	Hold
2023-04-20	Eingeleitet	Wells Fargo	Underweight
2022-12-13	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2022-11-14	Herabstufung	BofA Securities	Neutral → Underperform
2022-10-10	Herabstufung	Robert W. Baird	Outperform → Neutral
2022-06-30	Herabstufung	Jefferies	Buy → Hold
2022-06-03	Eingeleitet	CapitalOne	Equal Weight
2022-05-25	Hochstufung	Mizuho	Neutral → Buy
2022-04-18	Herabstufung	Barclays	Overweight → Equal Weight
2022-03-11	Hochstufung	BofA Securities	Underperform → Neutral
2022-02-18	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2022-02-01	Eingeleitet	Credit Suisse	Neutral
2021-10-08	Eingeleitet	Robert W. Baird	Outperform
2021-09-30	Hochstufung	Truist	Hold → Buy
2021-07-14	Resumed	Mizuho	Neutral
2021-05-21	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-10	Hochstufung	Stifel	Hold → Buy
2021-01-13	Hochstufung	Jefferies	Hold → Buy
2021-01-13	Herabstufung	Mizuho	Buy → Neutral
2021-01-08	Hochstufung	BMO Capital Markets	Underperform → Market Perform
2020-12-03	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2020-09-02	Resumed	Stifel	Hold
2020-06-23	Hochstufung	Scotiabank	Sector Underperform → Sector Perform
2020-06-08	Resumed	JMP Securities	Mkt Perform
2020-05-18	Hochstufung	Berenberg	Hold → Buy
2020-03-23	Herabstufung	BofA/Merrill	Neutral → Underperform
2020-02-26	Hochstufung	Mizuho	Neutral → Buy
2020-02-05	Eingeleitet	Berenberg	Hold
2019-12-20	Eingeleitet	Mizuho	Neutral
2019-12-18	Hochstufung	Citigroup	Sell → Neutral
2019-10-14	Resumed	BofA/Merrill	Neutral
2019-09-23	Herabstufung	Citigroup	Neutral → Sell
2019-09-03	Eingeleitet	Barclays	Overweight
2018-12-18	Herabstufung	SunTrust	Buy → Hold
2018-11-16	Herabstufung	BofA/Merrill	Neutral → Underperform
2018-05-21	Hochstufung	Raymond James	Mkt Perform → Outperform
2018-03-26	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-02-22	Bestätigt	Stifel	Hold
2017-12-21	Herabstufung	Jefferies	Buy → Hold
2017-09-25	Eingeleitet	CapitalOne	Equal Weight

Finanzdaten der Sabra Healthcare Reit Inc-Aktie (SBRA)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	774.63	703.24	647.51	624.81	569.55
Operating expenses USD (M)	-	-	628.86	603.14	488.88
Operating income USD (M)	-	-	18.66	21.67	80.67
Income before tax USD (M)	153.42	128.11	18.66	21.67	80.67
Income tax expense USD (M)	1.84	1.01	2.00	1.24	1.85
Net income USD (M)	155.51	126.71	13.76	-77.61	-113.26
Basic EPS USD/shares	0.64	0.54	0.06	-0.34	-0.52
Diluted EPS USD/shares	0.64	0.54	0.06	-0.34	-0.52
Basic weighted shares shares (M)	241.31	233.50	231.20	230.95	219.07
Diluted weighted shares shares (M)	244.50	236.05	232.79	230.95	219.07

Sabra Healthcare Reit Inc-Aktie (SBRA) Insiderhandel

Richard K. MatrosSep 08 '26
CEO
Transaktion
Proposed Sale
Kosten
$20.75
#Aktien
200,000
Wert ($)
4,150,000
#Aktien Gesamt
0
FLORES JESSICAMar 25 '26
Executive VP & CAO
Transaktion
Sale
Kosten
$19.86
#Aktien
15,231
Wert ($)
302,488
#Aktien Gesamt
71,709

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Richard K. Matros	CEO	Sep 08 '26	Proposed Sale	$20.75	200,000	4,150,000	0
FLORES JESSICA	Executive VP & CAO	Mar 25 '26	Sale	$19.86	15,231	302,488	71,709

Sabra Healthcare Reit Inc Aktie (SBRA) Neueste Nachrichten

Oct 27, 2026